Agios Pharmaceuticals (AGIO) Research & Development (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly Research & Development came in at $100.8 million in Q2 2026, up 9.59% YoY from $91.9 million in Q2 2025, and up 24.16% on a QoQ basis from $81.1 million in Q1 2026.
Agios Pharmaceuticals (AGIO) Research & Development (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 15 years of Research & Development data on file, last reported at $100.8 million in Q2 2026.
- Quarterly Research & Development rose 9.59% year-over-year to $100.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $356.8 million (up 11.5% YoY) and the FY2025 annual result came in at $339.5 million, up 12.7% from the prior year.
- Research & Development climbed to $100.8 million in Q2 2026, from $81.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $100.8 million in Q2 2026 to a low of $65.0 million in Q3 2022.
- A 5-year average of $77.7 million and a median of $76.0 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development grew 25.98% — and 2024, when it retreated 11.47%.
- Tracing AGIO's Research & Development over 5 years: stood at $70.3 million in 2022, then rose by 10.23% to $77.5 million in 2023, then grew by 6.87% to $82.8 million in 2024, then rose by 6.33% to $88.1 million in 2025, then climbed by 14.42% to $100.8 million in 2026.
- The last three Research & Development figures came in at $100.8 million (Q2 2026), $81.1 million (Q1 2026), and $88.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Agios Pharmaceuticals | 2.00 Bn | 1.38 Bn | 41.75 Mn | 100.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.75 Mn |
| Mar 31, 2026 | 81.15 Mn |
| Dec 31, 2025 | 88.06 Mn |
| Sep 30, 2025 | 86.80 Mn |
| Jun 30, 2025 | 91.94 Mn |
| Mar 31, 2025 | 72.74 Mn |
| Dec 31, 2024 | 82.81 Mn |
| Sep 30, 2024 | 72.46 Mn |
| Jun 30, 2024 | 77.40 Mn |
| Mar 31, 2024 | 68.62 Mn |
| Dec 31, 2023 | 77.49 Mn |
| Sep 30, 2023 | 81.84 Mn |
| Jun 30, 2023 | 68.90 Mn |
| Mar 31, 2023 | 67.30 Mn |
| Dec 31, 2022 | 70.30 Mn |
| Sep 30, 2022 | 64.97 Mn |
| Jun 30, 2022 | 74.52 Mn |
| Mar 31, 2022 | 70.12 Mn |
| Dec 31, 2021 | 73.30 Mn |
| Sep 30, 2021 | 64.00 Mn |